Mitigating MACE Risk in T2D & ASCVD

What strategies and guidelines can we use to reduce the risk of cardiovascular events in patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD)? Join leading experts in this four-part series to find out.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved.
US22DI00407 December 2022